The preparation of an acceptable placebo for NPH insulin.
A suitable placebo for NPH insulin has not previously been available for clinical investigation. A series of organic and inorganic compounds were formulated as insulin placebos and analyzed according to the following criteria: (1) degree of visual similarity to insulin, (2) stability, (3) absence of local side effects, and (4) clinical safety. Dilute suspensions of cortisone acetate (1.25-2.5 mg/ml) were found to fulfill the criteria as acceptable insulin placebos. Placebo-controlled studies with NPH insulin can now be performed.
D002986:Clinical Trials as Topic; D003348:Cortisone / Q000031:analogs & derivatives*; D006801:Humans; D007336:Insulin, Isophane / Q000627:therapeutic use*; D010919:Placebos / Q000627:therapeutic use*; D013535:Suspensions
D010919:Placebos; D013535:Suspensions; D007336:Insulin, Isophane; D003348:Cortisone